While conventional AChE inhibitors fail to halt the progression of AD, multitarget-directed ligands (MTDLs) can simultaneously reduce Aβ plaque formation, and fight neuroinflammation, among other effects, positively impacting disease progression [6,7,8,9]. Here, ACHE is linked to Alzheimer disease.